Asterias Biotherapeutics (NYSEMKT: AST), a clinical-stage biotechnology company, focuses on developing and commercializing novel therapies in the fields of cell therapy and regenerative medicine.
AST develops therapeutic products in the areas of neurology and oncology.
Its clinical stage programs include AST-OPC1, a therapy derived from pluripotent stem cells that has completed a Phase I clinical trial for the treatment of thoracic spinal cord injuries; and that is in Phase I/IIa clinical trial for treating cervical spinal cord injuries, as well as for the treatment of multiple sclerosis and white matter stroke. AST also develops immunotherapeutic programs, such as AST-VAC1, an autologous product candidate that has completed a Phase II clinical trial for the treatment of acute myelogenous leukemia; and AST-VAC2, which is in a Phase I/IIa clinical trial, an allogeneic and cancer vaccine candidate designed to stimulate patient immune responses to telomerase.
Asterias Biotherapeutics was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California. Asterias Biotherapeutics, Inc. is a subsidiary of BioTime, Inc.
June 16, 2021
Q2/21 Earnings - (LPS - loss-per-share) Results
June 16, 2021
RegMed Investors’ (RMi) pre-open: Waiting for Powell
June 15, 2021
RegMed Investors’ (RMi) pre-open: are you ready …
35 companies, 1 interpreter!
Insight, foresight and recommendation
Asterias Biotherapeutics (NYSE MKT: AST) - January'18 opened at $2.15, dropping to $2.00 on February 1 yet returning to $2.10 on 2/16 ... 2018 could bring some milestonesbuy
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at email@example.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors